PI Industries Q1 Review - Time To Replicate Proven Capabilities Of Agchem In Pharma: Prabhudas Lilladher

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..Prabhudas Lilladher Report.PI Industries Ltd. reported lower than expected results due to weak demand in domestic market, lower than anticipated custom synthesis manufacturing exports and cost overruns. PI Industries entered into an agreement to acquire active pharma ingredient and intermediate business unit of Ind-Swift Labs on slump sale basis for Rs 15.3 billion. Further, management highlighted scope of improvement from: existing ISLL portfoliocombining portfolio pipeline of both companies and implementing best commercial practices at ISLL. While we await more clarity from the management regarding value accretion and financial benefits from their transaction, the deal looks inexpensive in our view given regulatory approvals of plants, quality of facilities and scope of throughput improvement..Click on the attachment to read the full report:.DISCLAIMERThis report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

PI Industries Q1 Review - Time To Replicate Proven Capabilities Of Agchem In Pharma: Prabhudas Lilladher

PI Industries Q1 Review - Time To Replicate Proven Capabilities Of Agchem In Pharma: Prabhudas Lilladher

Choose a plan